Literature DB >> 10418761

Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria.

M A van Agtmael1, S Cheng-Qi, J X Qing, R Mull, C J van Boxtel.   

Abstract

Multiple dose pharmacokinetics of artemether and dihydroartemisinin were investigated in chinese patients treated for malaria. They received over 2 days either 4 x 80 mg artemether orally (n = 48) or 4 x 80-480 mg co-artemether (n = 40), a combination of artemether and lumefantrine (benflumetol). Lag time = 0.48 h (mean), Cmax after first dose = 157 ng/ml, t(max) = 1.73 h and elimination half-life = 1.16 h. The lag and absorption times were 0.5 h longer for co-artemether compared with artemether. Dihydroartemisinin paralleled artemether pharmacokinetics. Artemether Cmax after the last dose was one-third of the Cmax after the first dose while, inversely, dihydroartemisinin Cmax increased over time. We suggest that auto-induction of gut mucosa enzymes and/or liver enzymes causes a time-dependent increase in first-pass metabolisation of artemether.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10418761     DOI: 10.1016/s0924-8579(99)00063-1

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  39 in total

Review 1.  Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria.

Authors:  A A A Omari; C Gamble; P Garner
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

Review 2.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Clinical pharmacokinetic drug interactions associated with artemisinin derivatives and HIV-antivirals.

Authors:  Tony K L Kiang; Kyle J Wilby; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447

4.  Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.

Authors:  Sam Salman; Madhu Page-Sharp; Susan Griffin; Kaye Kose; Peter M Siba; Kenneth F Ilett; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

5.  Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in African children with malaria.

Authors:  Sam Salman; Daryl Bendel; Toong C Lee; David Templeton; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

6.  Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in healthy adults.

Authors:  Sam Salman; Daryl Bendel; Toong C Lee; David Templeton; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

7.  Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.

Authors:  T Kredo; K Mauff; J S Van der Walt; L Wiesner; G Maartens; K Cohen; P Smith; K I Barnes
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

8.  Endoperoxide Drug Cross-Resistance Patterns for Plasmodium falciparum Exhibiting an Artemisinin Delayed-Clearance Phenotype.

Authors:  A Siriwardana; K Iyengar; P D Roepe
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

9.  A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria.

Authors:  Y Suputtamongkol; P N Newton; B Angus; P Teja-Isavadharm; D Keeratithakul; M Rasameesoraj; S Pukrittayakamee; N J White
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

10.  Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects.

Authors:  Gilbert Lefèvre; Polly Carpenter; Claire Souppart; Heinz Schmidli; Mark McClean; Daria Stypinski
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.